Continue Reading Below
After Aratana Therapeutics(NASDAQ: PETX),a biotech company focused on pet health,announced the delay of a new product launch, shares fell 17% as of 11:15 a.m. EST on Monday.
The pet therapeutics company disclosed in a Securities and Exchange Commission filing on Monday that the Food and Drug Administration's Center for Veterinary Medicine (CVM) has requested more information about its appetite stimulant Entyce. Specifically, the CVM is looking for additional data related to the company's plans to transfer the manufacturing of Entyce to a new vendor.
According to Aratana, this unexpected information request is going to delay the drug's launch until late 2017.Investors are not taking the news well, hence today's decline.
Image source: Getty Images.
Aratana gained FDA approval for Entyce way back in May 2016, so this update means that it will take the company more than a year to bring this drug to market. That's never a good sign for any biotech company, let alone one that is still losing money each quarter.
On the positive side, the delay should also allow Aratana to throw more of its resources behind the launch of Nocita. This drug is approved for use in dogs as post-operative analgesia followingcranial cruciate ligament surgery. Management stated that gaining market adoption for this drug will take quite a bit of time since access to the surgeons who perform this procedure is much harder than selling to general practitioners. In addition, Monday's update doesn't change the fact thatEnctye'smarket potential remains quite large.
Still, delays are never good, so it is hard to blame the markets for punishing the company's stock today.
10 stocks we like better than Aratana TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Aratana Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017